Aptagen, LLC
TAFapt1-S (ID# 8078)
RNA
AML1-MTG8
Protein
4.47 nM (reported value)
Binding buffer [20 mM sodium phosphate (pH 6.5), 2 mM magnesium acetate, 200 mM potassium acetate, 5% glycerol, 0.05% Triton X-100, 5 mM b-mercaptoethanol].
Binding buffer [20 mM Tris/HCl (pH 7.5) containing 50 mM KCl and 1 mM DTT].
25°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
5'-rGprGprGprUprUprUprUprCprGprGprGprAprUprAprCprGprCprGprGprAprGprGprGprUprGprGprGprCprAprAprUprAprAprCprCprCprCp-3'
37
11413.3
348600
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Fukunaga, Junichi et al. “A G-quadruplex-forming RNA aptamer binds to the MTG8 TAFH domain and dissociates the leukemic AML1-MTG8 fusion protein from DNA.” FEBS letters vol. 594,21 (2020): 3477-3489. doi:10.1002/1873-3468.13914
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.